Adenosine and its receptors: Multiple modulatory functions and potential therapeutic targets for neurologic disease

Neurology

Volumn 70, Issue 3, 2008, Pages 231-236

  Benarroch, Eduardo E ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE KINASE; ADENOSINE PHOSPHATE; ADENOSINE RECEPTOR; ADENOSINE TRIPHOSPHATE; DIAZEPAM; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER; GUANINE NUCLEOTIDE BINDING PROTEIN; ISTRADEFYLLINE; PHENOBARBITAL; VALPROIC ACID;

ALCOHOL INTOXICATION; ARTICLE; BASAL GANGLION; BRAIN ISCHEMIA; CELL MEMBRANE; CELL METABOLISM; CELL SURVIVAL; CELL TYPE; DRUG TARGETING; EPILEPSY; EXCITOTOXICITY; HUMAN; HUNTINGTON CHOREA; METABOLIC STRESS; METABOLISM; NERVOUS SYSTEM; NEUROLOGIC DISEASE; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; PAIN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN FUNCTION; PROTEIN TARGETING; RECEPTOR UPREGULATION; SEIZURE; SIGNAL TRANSDUCTION; SLEEP INDUCTION;

EID: 38149003880     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000297939.18236.ec     Document Type: Article

References (30)

1. Fredholm BB, Chen JF, Masino SA, Vaugeois JM. Actions of adenosine at its receptors in the CNS: insights from knockouts and drugs. Annu Rev Pharmacol Toxicol 2005;45:385-412.
2. Dunwiddie TV, Masino SA. The role and regulation of adenosine in the central nervous system. Annu Rev Neurosci 2001;24:31-55.
3. Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 2006;5:247-264.
4. Ribeiro JA, Sebastiao AM, de Mendonca A. Adenosine receptors in the nervous system: pathophysiological implications. Prog Neurobiol 2002;68:377-392.
5. Bosion D. Adenosine kinase, epilepsy and stroke: mechanisms and therapies. Trends Pharmacol Sci. 2006;27:652-658.
6. Pagonopoulou O, Efthimiadou A, Asimakopoulos B, Nikolettos NK. Modulatory role of adenosine and its receptors in epilepsy: possible therapeutic approaches. Neurosci Res 2006;56:14-20.
7. Basheer R, Strecker RE, Thakkar MM, McCarley RW. Adenosine and sleep-wake regulation. Prog Neurobiol 2004;73:379-396.
8. Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M. Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci 2006;29:647-654.
9. Sawynok J, Liu XJ. Adenosine in the spinal cord and periphery: release and regulation of pain. Prog Neurobiol 2003;69:313-340.
10. Shi Y, Liu X, Gebremedhin D, Falck JR, Harder DR, Koehler RC. Interaction of mechanisms involving epoxyeicosatrienoic acids, adenosine receptors, and metabotropic glutamate receptors in neurovascular coupling in rat whisker barrel cortex. J Cereb Blood Flow Metab 2007 May 23 [ePub ahead of print].
11. Lahiri S, Mitchell CH, Reigada D, Roy A, Cherniack NS. Purines, the carotid body and respiration. Respir Physiol Neurobiol 2007;157:123-129.
12. Ribeiro JA. What can adenosine neuromodulation do for neuroprotection? Curr Drug Targets CNS Neurol Disord 2005;4:325-329.
13. During MJ, Spencer DD. Adenosine: a potential mediator of seizure arrest and postictal refractoriness. Ann Neurol 1992;32:618-624.
14. Schapira AH, Bezard E, Brotchie J, et al. Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov 2006;5:845-854.
15. Blum D, Hourez R, Galas MC, Popoli P, Schiffmann SN. Adenosine receptors and Huntington's disease: implications for pathogenesis and therapeutics. Lancet Neurol 2003;2:366-374.
16. King AE, Ackley MA, Cass CE, Young JD, Baldwin SA. Nucleoside transporters: from scavengers to novel therapeutic targets. Trends Pharmacol Sci 2006;27:416-425.
17. Hasko G, Pacher P, Vizi ES, Illes P. Adenosine receptor signaling in the brain immune system. Trends Pharmacol Sci 2005;26:511-516.
18. Zuchora B, Wielosz M, Urbanska EM. Adenosine A1 receptors and the anticonvulsant potential of drugs effective in the model of 3-nitropropionic acid-induced seizures in mice. Eur Neuropsychopharmacol 2005;15:85-93.
19. Elmenhorst D, Meyer PT, Winz OH, et al. Sleep deprivation increases A1 adenosine receptor binding in the human brain: a positron emission tomography study. J Neurosci 2007;27:2410-2415.
20. Retey JV, Adam M, Khatami R, et al. A genetic variation in the adenosine A2A receptor gene (ADORA2A) contributes to individual sensitivity to caffeine effects on sleep. Clin Pharmacol Ther 2007;81:692-698.
21. Bara-Jimenez W, Sherzai A, Dimitrova T, et al. Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology 2003;61:293-296.
22. Calon F, Dridi M, Hornykiewicz O, Bedard PJ, Rajput AH, Di Paolo T. Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain 2004;127(Pt 5):1075-1084.
23. Xu K, Bastia E, Schwarzschild M. Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease. Pharmacol Ther 2005;105:267-3121.
24. Hauser RA, Hubble JP, Truong DD. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology 2003;61:297-303.
25. Goadsby PJ, Hoskin KL, Storer RJ, Edvinsson L, Connor HE. Adenosine A1 receptor agonists inhibit trigeminovascular nociceptive transmission. Brain 2002;125(Pt 6):1392-1401.
26. Diener HC, Pfaffenrath V, Pageler L, Peil H, Aicher B. The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia 2005;25:776-787.
27. Hohoff C, Marziniak M, Lesch KP, Deckert J, Sommer C, Mossner R. An adenosine A2A receptor gene haplotype is associated with migraine with aura. Cephalalgia 2007;27:177-181.
28. Hayashida M, Fukuda K, Fukunaga A. Clinical application of adenosine and ATP for pain control. J Anesth 2005;19:225-235.
29. Lynch ME, Clark AJ, Sawynok J. Intravenous adenosine alleviates neuropathic pain: a double blind placebo controlled crossover trial using an enriched enrollment design. Pain 2003;103:111-117.
30. Choi DS, Cascini MG, Mailliard W, et al. The type 1 equilibrative nucleoside transporter regulates ethanol intoxication and preference. Nat Neurosci 2004;7:855-861.